SEC Tracker
Get the app

Tactile Systems Technology TCMD

Tactile Systems Technology reports Q3 2026 results

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Revenue increased 7% YoY to $91.9M
  2. Net income decreased to $7.2M from $8.2M
  3. Gross margin expanded to 77%
  4. Repurchased $6.2M in stock

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Tactile Systems Technology files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

  1. The press release is attached as Exhibit 99.1.
  2. Revenue from the lymphedema product line increased 13% to $81.8 million.
  3. Gross margin expanded to 77% from 76% in the third quarter of 2025.
  4. Adjusted EBITDA was $14.3 million, slightly lower than $14.4 million in the third quarter of 2025.
  5. The company also repurchased $6.2 million in stock.
  6. Reuters reported that Tactile Systems Technology, Inc. received FDA 510(k) clearance for the LymphaTech 3D Scanner to aid in lymphedema assessment.
  7. The company also submitted a 510(k) application for Flexitouch ® Pro, featuring enhancements to its compression system.

7 of 7 claims matched the filing text.

From the filing

Item 2.02. Results of Operations and Financial Condition.

Item 2.02. Results of Operations and Financial Condition.

On November 2, 2026, Tactile Systems Technology, Inc. ("we," "us," and "our") issued a press release disclosing our results of operations and financial condition for our most recently completed fiscal quarter. A copy of the press release is attached hereto as Exhibit 99.1.1

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 2.02, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in that filing.

Item 9.01. Financial Statements and Exhibits.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

EXHIBIT INDEX

Exhibit

No.

Description

99.1

Press Release dated November 2, 2026 (Earnings Release)

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TACTILE SYSTEMS TECHNOLOGY, INC.

Date: November 2, 2026

By:

/s/ E laine M. Birkemeyer

Elaine M. Birkemeyer

Chief Financial Officer

Tactile Systems Technology, Inc. Reports Third Quarter 2026 Financial Results

MINNEAPOLIS, MN, November 2, 2026 – Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the third quarter ended September 30, 2026 .

Third Quarter 2026 Summary and Recent Business Highlights:

● Total revenue increased 7% year-over-year to $91.9 million; revenue from our lymphedema product line increased 13% year-over-year to $81.8 million2 ● Gross margin expanded to 77% from 76% in Q3 20253 ● Net income decreased to $7.2 million from $8.2 million in Q3 2025 ● Adjusted EBITDA was $14.3 million, compared to $14.4 million in Q3 20254

● Received FDA 510(k) clearance expanding the LymphaTech 3D Scanner's indication to aid in the assessment of lymphedema6

● Submitted a 510(k) application to the FDA for Flexitouch ® Pro, featuring enhancements to the Company's advanced pneumatic compression system7

● Appointed Steve Kiewiet as Chief Operating Officer, with responsibility for order operations and patient services

● Repurchased $6.2 million of stock under the Company's share repurchase program5

" Our results underscore the strength and durability of our core lymphedema business, which delivered its fifth consecutive quarter of double-digit year-over-year

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. Electromed ELMD public float $224M, Dec 31, 2025
  2. Orasure Technologies OSUR public float $218M, Jun 30, 2025
  3. Cerus CERS public float $230M, Jun 30, 2025
  4. SANUWAVE Health SNWV public float $233M, Jun 30, 2025
  5. Inogen INGN public float $190M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.